INTRA-CELLULAR THERAPIES INC (ITCI) Fundamental Analysis & Valuation

NASDAQ:ITCI • US46116X1019

Current stock price

131.87 USD
-0.05 (-0.04%)
At close:
131.92 USD
+0.05 (+0.04%)
After Hours:

This ITCI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ITCI Profitability Analysis

1.1 Basic Checks

  • In the past year ITCI has reported negative net income.
  • ITCI had a negative operating cash flow in the past year.
  • In the past 5 years ITCI always reported negative net income.
  • ITCI had a negative operating cash flow in each of the past 5 years.
ITCI Yearly Net Income VS EBIT VS OCF VS FCFITCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • ITCI's Return On Assets of -5.46% is fine compared to the rest of the industry. ITCI outperforms 73.37% of its industry peers.
  • ITCI has a Return On Equity of -6.50%. This is in the better half of the industry: ITCI outperforms 78.39% of its industry peers.
Industry RankSector Rank
ROA -5.46%
ROE -6.5%
ROIC N/A
ROA(3y)-19.53%
ROA(5y)-29.65%
ROE(3y)-23.06%
ROE(5y)-34.34%
ROIC(3y)N/A
ROIC(5y)N/A
ITCI Yearly ROA, ROE, ROICITCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

  • Looking at the Gross Margin, with a value of 91.63%, ITCI belongs to the top of the industry, outperforming 94.97% of the companies in the same industry.
  • ITCI's Gross Margin has been stable in the last couple of years.
  • ITCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5YN/A
ITCI Yearly Profit, Operating, Gross MarginsITCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ITCI Health Analysis

2.1 Basic Checks

  • ITCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ITCI has more shares outstanding
  • ITCI has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for ITCI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ITCI Yearly Shares OutstandingITCI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ITCI Yearly Total Debt VS Total AssetsITCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • ITCI has an Altman-Z score of 38.03. This indicates that ITCI is financially healthy and has little risk of bankruptcy at the moment.
  • ITCI has a better Altman-Z score (38.03) than 97.49% of its industry peers.
  • There is no outstanding debt for ITCI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 38.03
ROIC/WACCN/A
WACC9.49%
ITCI Yearly LT Debt VS Equity VS FCFITCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • ITCI has a Current Ratio of 6.36. This indicates that ITCI is financially healthy and has no problem in meeting its short term obligations.
  • ITCI's Current ratio of 6.36 is fine compared to the rest of the industry. ITCI outperforms 76.38% of its industry peers.
  • A Quick Ratio of 6.23 indicates that ITCI has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 6.23, ITCI is in the better half of the industry, outperforming 76.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.36
Quick Ratio 6.23
ITCI Yearly Current Assets VS Current LiabilitesITCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ITCI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 50.00% over the past year.
  • Looking at the last year, ITCI shows a very strong growth in Revenue. The Revenue has grown by 46.61%.
  • Measured over the past years, ITCI shows a very strong growth in Revenue. The Revenue has been growing by 484.27% on average per year.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
Revenue 1Y (TTM)46.61%
Revenue growth 3Y101.03%
Revenue growth 5Y484.27%
Sales Q2Q%50.81%

3.2 Future

  • ITCI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 87.04% yearly.
  • The Revenue is expected to grow by 37.51% on average over the next years. This is a very strong growth
EPS Next Y127.35%
EPS Next 2Y174.17%
EPS Next 3Y140.69%
EPS Next 5Y87.04%
Revenue Next Year40.33%
Revenue Next 2Y50.81%
Revenue Next 3Y47.62%
Revenue Next 5Y37.51%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ITCI Yearly Revenue VS EstimatesITCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
ITCI Yearly EPS VS EstimatesITCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

1

4. ITCI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ITCI. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 660.59 indicates a quite expensive valuation of ITCI.
  • 73.37% of the companies in the same industry are more expensive than ITCI, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.28, ITCI is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 660.59
ITCI Price Earnings VS Forward Price EarningsITCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 200 400 600

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ITCI Per share dataITCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as ITCI's earnings are expected to grow with 140.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y174.17%
EPS Next 3Y140.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ITCI Dividend Analysis

5.1 Amount

  • ITCI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ITCI Fundamentals: All Metrics, Ratios and Statistics

INTRA-CELLULAR THERAPIES INC

NASDAQ:ITCI (4/1/2025, 8:00:02 PM)

After market: 131.92 +0.05 (+0.04%)

131.87

-0.05 (-0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-21
Earnings (Next)05-05
Inst Owners94.75%
Inst Owner Change-99.55%
Ins Owners0.23%
Ins Owner Change0%
Market Cap14.05B
Revenue(TTM)680.85M
Net Income(TTM)-74.68M
Analysts72.22
Price Target133.21 (1.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.8%
Min EPS beat(2)-40.63%
Max EPS beat(2)-24.97%
EPS beat(4)2
Avg EPS beat(4)0.62%
Min EPS beat(4)-40.63%
Max EPS beat(4)50.59%
EPS beat(8)6
Avg EPS beat(8)17.95%
EPS beat(12)9
Avg EPS beat(12)16.57%
EPS beat(16)10
Avg EPS beat(16)13.07%
Revenue beat(2)1
Avg Revenue beat(2)0.38%
Min Revenue beat(2)-0.24%
Max Revenue beat(2)1%
Revenue beat(4)3
Avg Revenue beat(4)0.36%
Min Revenue beat(4)-0.24%
Max Revenue beat(4)1%
Revenue beat(8)6
Avg Revenue beat(8)0.51%
Revenue beat(12)9
Avg Revenue beat(12)1.93%
Revenue beat(16)11
Avg Revenue beat(16)1.25%
PT rev (1m)-0.1%
PT rev (3m)26.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.86%
EPS NY rev (1m)-30.48%
EPS NY rev (3m)-47.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.15%
Revenue NY rev (1m)0.91%
Revenue NY rev (3m)1.41%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 660.59
P/S 20.63
P/FCF N/A
P/OCF N/A
P/B 12.23
P/tB 12.23
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)0.2
Fwd EY0.15%
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS6.39
BVpS10.78
TBVpS10.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.46%
ROE -6.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.63%
FCFM N/A
ROA(3y)-19.53%
ROA(5y)-29.65%
ROE(3y)-23.06%
ROE(5y)-34.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5YN/A
F-Score4
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 63.39%
Cap/Sales 0.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.36
Quick Ratio 6.23
Altman-Z 38.03
F-Score4
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)77.5%
Cap/Depr(5y)69.14%
Cap/Sales(3y)0.14%
Cap/Sales(5y)0.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
EPS Next Y127.35%
EPS Next 2Y174.17%
EPS Next 3Y140.69%
EPS Next 5Y87.04%
Revenue 1Y (TTM)46.61%
Revenue growth 3Y101.03%
Revenue growth 5Y484.27%
Sales Q2Q%50.81%
Revenue Next Year40.33%
Revenue Next 2Y50.81%
Revenue Next 3Y47.62%
Revenue Next 5Y37.51%
EBIT growth 1Y26.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year126.61%
EBIT Next 3Y133.69%
EBIT Next 5Y90.06%
FCF growth 1Y40.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.08%
OCF growth 3YN/A
OCF growth 5YN/A

INTRA-CELLULAR THERAPIES INC / ITCI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for INTRA-CELLULAR THERAPIES INC?

ChartMill assigns a fundamental rating of 5 / 10 to ITCI.


What is the valuation status of INTRA-CELLULAR THERAPIES INC (ITCI) stock?

ChartMill assigns a valuation rating of 1 / 10 to INTRA-CELLULAR THERAPIES INC (ITCI). This can be considered as Overvalued.


Can you provide the profitability details for INTRA-CELLULAR THERAPIES INC?

INTRA-CELLULAR THERAPIES INC (ITCI) has a profitability rating of 2 / 10.


Can you provide the financial health for ITCI stock?

The financial health rating of INTRA-CELLULAR THERAPIES INC (ITCI) is 8 / 10.